Abstract 135: Change in Cognition, Depression, and Anxiety Following Catheter Ablation
Background: Patients with atrial fibrillation (AF) commonly experience symptoms such as palpitations, shortness of breath and chest discomfort. The severity of AF-related symptoms is associated with psychosocial factors such as anxiety and depression. Limited data suggests that catheter ablation, a treatment option in symptomatic patients with AF, reduces depression and anxiety but its effect on cognitive function remains unclear.
Methods: Participants were 38 AF patients (mean age = 63 years ±8; 68% male, 66% paroxysmal AF) undergoing an index catheter ablation for AF at the University of Massachusetts Medical Center and interviewed pre-ablation and post ablation (1-week, 1 month and 3 months) as part of an ongoing study of AF treatment and psychosocial factors. A total of 150 ablation patients will be included in the final sample. Cognitive function was assessed using the Montreal Cognitive Assessment Battery (impairment = score <27 on the 30 point scale), depression by the Patient Health Questionnaire (PHQ) and anxiety by the Generalized Anxiety Score (GAD). Trajectories of depressive symptoms, anxiety and cognitive function were modeled before and after catheter ablation using linear mixed models adjusting for age, sex, AF type (paroxysmal vs other), and history of coronary artery disease or diabetes.
Results: Patients reported high levels of depressive symptoms and anxiety and many (>50%) were cognitively impaired prior to ablation. Cognitive function increased following ablation, with improvements observed as early as one week after catheter ablation and continued to improve at 3-months post procedure (Table). Symptoms of depression and anxiety declined immediately following ablation and continued to decline through 3-months post procedure but changes were not statistically significant and may have been limited by power.
Conclusions: Catheter-based ablation was associated with improved symptoms of depression and anxiety as well as cognitive function among patients with symptomatic AF. Knowledge of the patient-centered, as well as clinical, benefits of the various treatments for AF will guide patients, their families and their physicians make informed treatment choices.
Author Disclosures: J.S. Saczynski: None. H.M. Richardson: None. A. Hajduk: None. C.I. Kiefe: None. R.J. Goldberg: None. K.C. Floyd: None. L.S. Rosenthal: None. C. Browning: None. D.D. McManus: None.
- © 2014 by American Heart Association, Inc.